Professional Resources
Scientific Literature
Below are published studies on clinical trials of Cymbalta.
Duloxetine, 60 mg Once Daily, for Major Depressive Disorder: A Randomized Double-Blind Placebo-Controlled Trial
This multicenter, double-blind, parallel-group study of duloxetine 60 mg/day for 9 weeks found that duloxetine is significantly superior to placebo, reducing HAM-D17 total scores and painful physical symptoms associated with MDD.
Duloxetine Treatment for Role Functioning Improvement in Generalized Anxiety Disorder: Three Independent Studies
One 9-week and two 10-week studies of Cymbalta 60 and 120 mg/day found that patients treated with duloxetine improved significantly more than those treated with placebo, as measured by the Sheehan Disability Scale work, social life, and family/home responsibility scores. Each of these studies were randomized, double-blind, placebo-controlled multicenter trials.
Cymbalta for Fibromyalgia
Cymbalta is indicated for the management of fibromyalgia.
Register to Receive Information From Cymbalta
Keep up-to-date on the latest developments with Cymbalta. Sign up now for our periodic emails.
Thought Leader Podcasts
Listen to peers and experts discuss the latest advances in diagnosis and treatment for MDD, GAD, DPNP, and fibromyalgia.
Listen to the podcasts now.
